Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

chikungunya virus

- PMLiVE

MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults

The chikungunya virus has now been identified in over 110 countries in Europe, Asia, Africa and the Americas

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate

There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally

EU flag

EC approves Valneva’s single-dose chikungunya vaccine for use in adults

The virus has been identified in over 110 countries in Europe, Asia, Africa and the Americas

EU flag

CHMP recommends Valneva’s chikungunya vaccine for use in adults

If approved, Ixchiq will become the first vaccine available in the EU for the mosquito-borne viral disease

- PMLiVE

Valneva’s single-dose chikungunya vaccine shows promise in adolescents

The mosquito-borne viral disease often causes sudden, large outbreaks with high attack rates

- PMLiVE

Valneva’s chikungunya virus vaccine recommended by US CDC advisory committee

The mosquito-borne viral disease leads to symptomatic disease in 97% of people within a week or less following the mosquito bite

- PMLiVE

Valneva sells FDA priority review voucher for chikungunya vaccine for $103m

The company received a tropical disease PRV in November following the FDA’s approval of Ixchiq for the prevention of disease caused by chikungunya virus

- PMLiVE

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease

dengue fever mosquito

Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial

There is currently no approved vaccine or specific treatment for chikungunya virus infections

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links